348 related articles for article (PubMed ID: 25909083)
1. Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Spelman T; Kalincik T; Zhang A; Pellegrini F; Wiendl H; Kappos L; Tsvetkova L; Belachew S; Hyde R; Verheul F; Grand-Maison F; Izquierdo G; Grammond P; Duquette P; Lugaresi A; Lechner-Scott J; Oreja-Guevara C; Hupperts R; Petersen T; Barnett M; Trojano M; Butzkueven H
Ann Clin Transl Neurol; 2015 Apr; 2(4):373-87. PubMed ID: 25909083
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Spelman T; Kalincik T; Jokubaitis V; Zhang A; Pellegrini F; Wiendl H; Belachew S; Hyde R; Verheul F; Lugaresi A; Havrdová E; Horáková D; Grammond P; Duquette P; Prat A; Iuliano G; Terzi M; Izquierdo G; Hupperts RM; Boz C; Pucci E; Giuliani G; Sola P; Spitaleri DL; Lechner-Scott J; Bergamaschi R; Grand'Maison F; Granella F; Kappos L; Trojano M; Butzkueven H
Neurol Clin Pract; 2016 Apr; 6(2):102-115. PubMed ID: 27104064
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
5. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Spelman T; Mekhael L; Burke T; Butzkueven H; Hodgkinson S; Havrdova E; Horakova D; Duquette P; Izquierdo G; Grand'Maison F; Grammond P; Barnett M; Lechner-Scott J; Alroughani R; Trojano M; Lugaresi A; Granella F; Pucci E; Vucic S;
Eur J Neurol; 2016 Apr; 23(4):729-36. PubMed ID: 26782663
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
7. Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.
Cofield SS; Fox RJ; Tyry T; Salter AR; Campagnolo D
Int J MS Care; 2016; 18(5):230-238. PubMed ID: 27803638
[No Abstract] [Full Text] [Related]
8. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
9. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
10. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
Carrá A; Onaha P; Luetic G; Burgos M; Crespo E; Deri N; Halfon M; Jaacks G; López A; Sinay V; Vrech C
Eur J Neurol; 2008 Apr; 15(4):386-93. PubMed ID: 18353125
[TBL] [Abstract][Full Text] [Related]
12. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform.
Jokubaitis VG; Spelman T; Lechner-Scott J; Barnett M; Shaw C; Vucic S; Liew D; Butzkueven H; Slee M;
PLoS One; 2013; 8(3):e59694. PubMed ID: 23527252
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.
Butzkueven H; Kalincik T; Patti F; Slee M; Weinstock-Guttman B; Buzzard K; Skibina O; Alroughani R; Prat A; Girard M; Horakova D; Havrdova EK; Van der Walt A; Eichau S; Hyde R; Campbell N; Bodhinathan K; Spelman T;
Ther Adv Neurol Disord; 2024; 17():17562864231221331. PubMed ID: 38414723
[TBL] [Abstract][Full Text] [Related]
14. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
Oleen-Burkey M; Cyhaniuk A; Swallow E
J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon.
Chen C; Wu N; Watson C
Clinicoecon Outcomes Res; 2018; 10():723-730. PubMed ID: 30464565
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
18. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
19. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Johnson BH; Bonafede MM; Watson C
CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β.
Buron MD; Magyari M; Chalmer TA; Sørensen PS; Sellebjerg F
Mult Scler Relat Disord; 2020 Apr; 39():101894. PubMed ID: 31884382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
